PharmAthene has gained some powerful support in Washington for its plans to expand a herd of genetically modified goats used in drug research by housing the animals at a USDA facility in Maryland. One of the state's senators, Benjamin Cardin, has introduced a measure in the farm bill that would permit just that in a public-private partnership. PharmAthene has been developing Protexia--a therapy produced in goats' milk and used to protect people from nerve agents--under Project BioShield [1]. PharmAthene is also in a race to produce a new anthrax vaccine, a field where Human Genome Sciences is widely considered the leader.
- read the report [2] from The Washington Post
Related Articles:
PharmAthene to go public through merger. Report [3]
Siga Technologies, PharmAthene to merge. Report [4]
EMEA panel recommends goat-milk therapy. Report [5]
Links:
[1] http://www.fiercebiotech.com/story/more-rd-funds-allocated-for-project-bioshield/2006-12-12
[2] http://www.washingtonpost.com/wp-dyn/content/article/2008/01/13/AR2008011302330.html
[3] http://www.fiercebiotech.com/story/pharmathene-to-go-public-through-merger/2007-01-22
[4] http://www.fiercebiotech.com/story/siga-technologies-pharmathene-to-merge/2006-06-09
[5] http://www.fiercebiotech.com/story/emea-panel-recommends-goat-milk-therapy/2006-06-02